Donald Ogilvie

8.0k total citations · 3 hit papers
82 papers, 4.5k citations indexed

About

Donald Ogilvie is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Donald Ogilvie has authored 82 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 31 papers in Oncology and 18 papers in Genetics. Recurrent topics in Donald Ogilvie's work include Connective tissue disorders research (15 papers), HER2/EGFR in Cancer Research (12 papers) and Angiogenesis and VEGF in Cancer (12 papers). Donald Ogilvie is often cited by papers focused on Connective tissue disorders research (15 papers), HER2/EGFR in Cancer Research (12 papers) and Angiogenesis and VEGF in Cancer (12 papers). Donald Ogilvie collaborates with scholars based in United Kingdom, France and United States. Donald Ogilvie's co-authors include Bryan Sykes, B P Wordsworth, Stephen R. Wedge, Jane Kendrew, Laurent Hennequin, Jon Curwen, Andrew P. Thomas, Elaine S. E. Stokes, Rakesh Anand and Nigel J. Jones and has published in prestigious journals such as The Lancet, Nucleic Acids Research and JNCI Journal of the National Cancer Institute.

In The Last Decade

Donald Ogilvie

82 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

2002 702 citations Stephen R. Wedge, Donald Ogilvie et al. profile →
A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clones

1990 569 citations J. Riley, Rachel Butler et al. Nucleic Acids Research profile →
The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells

2012 432 citations William J. Harris, Xu Huang et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donald Ogilvie United Kingdom	31	2.6k	1.3k	859	625	501	82	4.5k
Olaf Witt Germany	40	4.6k 1.7×	1.6k 1.2×	378 0.4×	587 0.9×	628 1.3×	163	6.7k
Antonino Passaniti United States	39	3.6k 1.4×	1.1k 0.8×	437 0.5×	549 0.9×	1.5k 2.9×	85	5.6k
Jeffrey A. Medin Canada	40	3.0k 1.1×	1.2k 0.9×	966 1.1×	276 0.4×	409 0.8×	181	5.8k
D Kufe United States	35	3.1k 1.2×	1.5k 1.1×	423 0.5×	272 0.4×	716 1.4×	78	4.7k
Mark Merchant United States	32	3.1k 1.2×	1.6k 1.2×	601 0.7×	645 1.0×	591 1.2×	64	4.9k
Jimmie E. Fata United States	27	2.7k 1.0×	1.7k 1.3×	411 0.5×	279 0.4×	1.2k 2.4×	45	4.6k
Gregory Hollis United States	36	2.7k 1.0×	1.0k 0.8×	548 0.6×	154 0.2×	369 0.7×	101	5.1k
Grazia Ambrosini United States	27	4.8k 1.8×	2.2k 1.7×	386 0.4×	643 1.0×	743 1.5×	48	6.8k
Domenico Delia Italy	43	4.2k 1.6×	2.5k 1.9×	565 0.7×	462 0.7×	1.2k 2.4×	125	6.9k
Lynn G. Feun United States	39	2.2k 0.8×	1.8k 1.4×	562 0.7×	817 1.3×	1.1k 2.1×	207	5.7k

Countries citing papers authored by Donald Ogilvie

Since Specialization

Citations

This map shows the geographic impact of Donald Ogilvie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Ogilvie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Ogilvie more than expected).

Fields of papers citing papers by Donald Ogilvie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald Ogilvie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Ogilvie. The network helps show where Donald Ogilvie may publish in the future.

Co-authorship network of co-authors of Donald Ogilvie

This figure shows the co-authorship network connecting the top 25 collaborators of Donald Ogilvie. A scholar is included among the top collaborators of Donald Ogilvie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald Ogilvie. Donald Ogilvie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hornyak, P., Trevor Askwith, Sarah Walker, et al.. (2016). Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2. Biochemical Journal. 473(13). 1869–1879. 32 indexed citations

Barlaam, Bernard, Judith Anderton, Peter Ballard, et al.. (2013). Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Medicinal Chemistry Letters. 4(8). 742–746. 31 indexed citations

Harris, William J., Xu Huang, James T. Lynch, et al.. (2012). The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells. Cancer Cell. 21(4). 473–487. 432 indexed citations breakdown →

Brave, Sandra R., Kirsty Ratcliffe, Zena Wilson, et al.. (2011). Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family. Molecular Cancer Therapeutics. 10(5). 861–873. 72 indexed citations

Hickinson, D. Mark, Teresa Klinowska, Georgina Speake, et al.. (2010). AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer. Clinical Cancer Research. 16(4). 1159–1169. 95 indexed citations

Wedge, Stephen R., Teresa Klinowska, Neil R. Smith, et al.. (2007). Examining inhibition of VEGFR and EGFR signaling in MMTV-neu transgenic mice with well-established tumors: an immunohistochemical and oncogenomic analysis of AZD2171, vandetanib and gefitinib treatment. Cancer Research. 67. 2122–2122. 1 indexed citations

Ducray, Richard, et al.. (2007). Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(3). 959–962. 70 indexed citations

Barlaam, Bernard, Peter Ballard, Robert H. Bradbury, et al.. (2007). A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 18(2). 674–678. 18 indexed citations

Ballard, Peter, Robert H. Bradbury, Craig S. Harris, et al.. (2005). Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. Bioorganic & Medicinal Chemistry Letters. 16(6). 1633–1637. 31 indexed citations

10.

Wedge, Stephen R., Jane Kendrew, Jon Curwen, et al.. (2004). The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo. Cancer Research. 64. 1052–1052. 7 indexed citations

11.

Drevs, Joachim, N. Esser, Stephen R. Wedge, et al.. (2004). Effect of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma. 64. 1051–1052. 8 indexed citations

12.

Ogilvie, Donald & Louise James. (2003). End Rescue from YACs Using the Vectorette. Humana Press eBooks. 54. 131–138. 3 indexed citations

13.

Heppell-Parton, Amanda, Elizabeth Nacheva, Nigel P. Carter, et al.. (1999). Elucidation of the Mechanism of Homozygous Deletion of 3p12∼13 in the U2020 Cell Line Reveals the Unexpected Involvement of Other Chromosomes. Cancer Genetics and Cytogenetics. 111(2). 105–110. 2 indexed citations

14.

Sundaresan, Vasi, Grace Chung, Amanda Heppell-Parton, et al.. (1998). Homozygous deletions at 3p12 in breast and lung cancer. Oncogene. 17(13). 1723–1729. 97 indexed citations

15.

Bailey, Andy M., J.P. Leek, Patricia M. Clissold, et al.. (1995). Yeast artificial chromosome cloning of the ?-catenin locus on human chromosome 3p21?22. Chromosome Research. 3(3). 201–203. 7 indexed citations

16.

Riley, J., Rachel Butler, Donald Ogilvie, et al.. (1990). A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clones. Nucleic Acids Research. 18(10). 2887–2890. 569 indexed citations breakdown →

17.

Aitchison, Katherine J., et al.. (1988). Homozygous osteogenesis imperfecta unlinked to collagen I genes. Human Genetics. 78(3). 233–236. 50 indexed citations

18.

Ogilvie, Donald, B P Wordsworth, L. Priestley, et al.. (1987). Segregation of all four major fibrillar collagen genes in the Marfan syndrome.. Europe PMC (PubMed Central). 41(6). 1071–82. 34 indexed citations

19.

Ogilvie, Donald, et al.. (1986). Evidence against the structural gene encoding type II collagen (COL2A1) as the mutant locus in achondroplasia.. Journal of Medical Genetics. 23(1). 19–22. 28 indexed citations

20.

Ogilvie, Donald, et al.. (1976). Urinary outputs of oxalate, calcium, and magnesium in children with intestinal disorders. Potential cause of renal calculi.. Archives of Disease in Childhood. 51(10). 790–795. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact